Targeted therapy in advanced bladder cancer: what have we learned? Review uri icon

Overview

abstract

  • Despite advances in the treatment of other genitourinary malignancies, no novel therapies have been approved by the US Food and Drug Administration for urothelial carcinoma (UC) in the last 20 years. To date, no clinical trials of targeted agents in UC have led to improvements in survival compared with cytotoxic therapy. This article outlines representative trials of targeted therapies in UC and discusses the significance of genetic preselection in trial design as a method to optimize responses to these agents, thus, hopefully expanding the armamentarium of treatment options against this lethal disease.

publication date

  • March 12, 2015

Research

keywords

  • Carcinoma, Transitional Cell
  • Molecular Targeted Therapy
  • Protein Kinase Inhibitors
  • Urinary Bladder Neoplasms

Identity

PubMed Central ID

  • PMC4939834

Scopus Document Identifier

  • 84955350871

Digital Object Identifier (DOI)

  • 10.1016/j.ucl.2015.01.006

PubMed ID

  • 25882566

Additional Document Info

volume

  • 42

issue

  • 2